Novartis Pulling Out All The Stops To Amp Up Entresto Sales
This article was originally published in The Pink Sheet Daily
The company has set a sales goal of $200m for Entresto in 2016, not an enormous amount for a drug that is expected to eventually be a multi-billion dollar seller, but ambitious given its slow first quarter start.
You may also be interested in...
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.